Prehliadač alebo jeho nastavenia nie sú podporované.

Praktik.ai používa moderné webové technológie kvôli bezpečnosti, rýchlosti a spoľahlivému prihlasovaniu. Tento prehliadač ich nepodporuje alebo blokuje JavaScript, preto sa aplikácia nemusí správne načítať.

Aktualizujte prosím Chrome, Edge, Firefox alebo Safari na najnovšiu verziu a stránku potom obnovte.

Ak používate Windows 7, Windows 8 alebo Windows 8.1, Chrome a Edge už nemusia ponúkať novú verziu. V takom prípade použite novšie zariadenie alebo kontaktujte podporu Praktik.ai.

Prohlížeč nebo jeho nastavení nejsou podporované.

Praktik.ai používá moderní webové technologie kvůli bezpečnosti, rychlosti a spolehlivému přihlašování. Tento prohlížeč je nepodporuje nebo blokuje JavaScript, proto se aplikace nemusí správně načíst.

Aktualizujte prosím Chrome, Edge, Firefox nebo Safari na nejnovější verzi a stránku potom obnovte.

Pokud používáte Windows 7, Windows 8 nebo Windows 8.1, Chrome a Edge už nemusí nabízet novou verzi. V takovém případě použijte novější zařízení nebo kontaktujte podporu Praktik.ai.

Your browser or its settings are not supported.

Praktik.ai uses modern web technologies for security, speed, and reliable sign-in. This browser does not support them, or JavaScript is blocked, so the app may not load correctly.

Please update Chrome, Edge, Firefox, or Safari to the latest version and then reload this page.

If you use Windows 7, Windows 8, or Windows 8.1, Chrome and Edge may no longer offer a newer version. In that case, use a newer device or contact Praktik.ai support.

Not effective COMMISSION REGULATION (EC) No 1353/2007 of 20 November 2007 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Monensin, Lasalocid and Tylvalosin (Text with EEA relevance)

Vyhláška č. 1353/2007

Text language

Important dates

Declared: 20. novembra 2007
Approved: 20. novembra 2007
Effective from: 24. novembra 2007
Effective until: 5. júla 2009

Documents and links

COMMISSION REGULATION (EC) No 1353/2007

of 20 November 2007

amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards Monensin, Lasalocid and Tylvalosin

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), and in particular Article 2 thereof,

Having regard to the opinion of the European Medicines Agency formulated by the Committee for Medicinal Products for Veterinary Use,

Whereas:

(1)

All pharmacologically active substances used in the Community in veterinary medicinal products intended for food-producing animals should be evaluated in accordance with Regulation (EEC) No 2377/90.

(2)

An application for establishing maximum residue limits for Monensin, an antibiotic and anticoccidial belonging to the group of ionophores, has been submitted to the European Medicines Agency. On the basis of the recommendation of the Committee for Medicinal Products for Veterinary Use, this substance should be added in Annex I to Regulation (EEC) No 2377/90 for bovine species (muscle, fat, liver, kidney and milk).

(3)

The substance Lasalocid is currently included in Annex I to Regulation (EEC) No 2377/90 for poultry for muscle, skin and fat, liver and kidney and in Annex III to Regulation (EEC) No 2377/90 for poultry from which eggs are produced for human consumption, awaiting validation of analytical method. Those scientific studies have been now completed and the analytical method has been validated by the Committee for Medicinal Products for Veterinary Use. Lasalocid belongs to the group of antibiotic ionophores having anticoccidial properties. Consequently, Lasalocid should be added in Annex I to Regulation (EEC) No 2377/90 for poultry from which eggs are produced for human consumption, under the new point 1.2.16, while the Lasalocid entry under point 2.4.4 of Annex I to Regulation (EEC) No 2377/90 should be deleted.

(4)

The substance Acetylisovaleryltylosin, an antibiotic belonging to the group of macrolides is currently included in Annex I to Regulation (EEC) No 2377/90 for porcine and poultry species. A change to the International Non-proprietary Name (INN) of this active substance has been notified to the European Medicines Agency. The substance’s name Acetylisovaleryltylosin should be replaced by the new INN, Tylvalosin.

(5)

Regulation (EEC) No 2377/90 should therefore be amended accordingly.

(6)

An adequate period should be allowed before the applicability of this Regulation in order to enable Member States to make any adjustment which may be necessary in the light of this Regulation to the authorisations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products (2) to take account of the provisions of this Regulation.

(7)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products,

HAS ADOPTED THIS REGULATION:

Article 1

Annex I to Regulation (EEC) No 2377/90 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the third day following its publication in the Official Journal of the European Union.

It shall apply from 20 January 2008.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 20 November 2007.

For the Commission

Günter VERHEUGEN

Vice-President

Prílohy

ANNEX

Annex I to Regulation (EEC) No 2377/90 is amended as follows:

(1)

in point 1.2.4, the entry for ‘Acetylisovaleryltylosin’ is replaced by the following:

1.2.4.   Macrolides

Pharmacologically active substance(s)

Marker residue

Animal species

MRLs

Target tissues

‘Tylvalosin

Sum of tylvalosin and 3-O-acetyltylosin

Porcine

50 μg/kg

Muscle

50 μg/kg

Fat (1)

50 μg/kg

Liver

50 μg/kg

Kidney

Poultry (2)

50 μg/kg

Fat (3)

50 μg/kg

Liver

(2)

the following point 1.2.16 is added:

1.2.16.   Ionophores

Pharmacologically active substance(s)

Marker residue

Animal species

MRLs

Target tissues

Monensin

Monensin A

Bovine

2 μg/kg

Muscle

10 μg/kg

Fat

30 μg/kg

Liver

2 μg/kg

Kidney

2 μg/kg

Milk

Lasalocid

Lasalocid A

Poultry

20 μg/kg

Muscle

100 μg/kg

Fat (4)

100 μg/kg

Liver

50 μg/kg

Kidney

150 μg/kg

Eggs

(3)

in point 2.4.4, the entry for ‘Lasalocid’ is deleted.

Poznámky

(1)   OJ L 224, 18.8.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1323/2007 (OJ L 294, 13.11.2007, p. 11).

(2)   OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (OJ L 136, 30.4.2004, p. 58).

(1)  For porcine species, this MRL relates to “skin and fat in natural proportions”.

(2)  Not for use in animals from which eggs are produced for human consumption.

(3)  For poultry species, this MRL relates to “skin and fat in natural proportions”.’

(4)  For poultry species, this MRL relates to “skin and fat in natural proportions”.’